PTPI Petros Pharmaceuticals (PTPI) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001815903
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Petros Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Petros Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 2.6% of the 5,703,544 shares held after it.
- 1 other insider bought within 30 days.
Insider activity: Director Juggernaut Partners III GP, L.P. bought about $500.0K of PTPI on Dec 22, 2021; 1 other insider bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 9.0% of the 5,557,771 shares held after it.
- 1 other insider bought within 30 days.
Insider activity: Director Juggernaut Partners III GP, Ltd. bought about $1.5M of PTPI on Nov 29, 2021; 1 other insider bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 32.9% of the 5,057,771 shares held after it.
- No other insider bought within 30 days.
Insider activity: Director SHULMAN JOHN D bought about $2.9M of PTPI on Oct 18, 2021, the largest insider purchase at the company on our record.3 transactions on record · a thin record, read with care
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
under five funds report holding it
Revenue
-12.2% year over year
below 66% of Pharma & Biotech
Margin
37.4% net margin
more than 93% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
0.2% of the float short (float per yahoo 2026-10-27) · 1.0 days to cover · settled 2026-10-15
below 87% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch PTPI
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-89.4%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PTPI: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in PTPI
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PTPI planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
Each figure here is a federal filing, dated the day it went public, so you can test what was knowable then.
PTPI financials
Revenue growth
-12.2%
XBRL, annual
Net margin
37.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$5.1M
four quarters, 2024-01-01 to 2024-12-31
Revenue, TTM PTPI
| FY Dec 2025 | $5.1M |
| FY Dec 2024 | $5.1M |
| FY Dec 2023 | $5.8M |
| FY Dec 2022 | $6.0M |
| FY Dec 2021 | $7.8M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $725.4K |
| Sep 2024 | $1.6M |
At each fiscal year end
Single quarter
Net margin, TTM
-62.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PTPI
| FY Dec 2025 | +37.4% |
| FY Dec 2024 | -280.1% |
| FY Dec 2023 | -140.2% |
| FY Dec 2022 | -334.4% |
| FY Dec 2021 | -115.0% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -1,278% |
| Sep 2024 | -140.9% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM PTPI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -$7.6M |
| FY Dec 2022 | -$12.8M |
| FY Dec 2021 | -$11.9M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $960.0K |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
2.48x
current debt only, 2021-09-30 (57 months older than the period end); equity 2026-06-30
Debt to equity PTPI
| FY Dec 2025 | 0.61x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | 0.14x |
| FY Dec 2022 | 0.10x |
| FY Dec 2021 | 0.05x |
| Jun 2026 | 2.48x |
| Mar 2026 | 0.98x |
| Dec 2025 | 0.61x |
| Sep 2025 | 0.52x |
| Jun 2025 | 0.39x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | 0.56x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-2.13x
TTM operating cash flow over current debt only, 2021-09-30 (57 months older than the period end)
Cash flow to debt PTPI
| FY Dec 2025 | -3.87x |
| FY Dec 2024 | -1.50x |
| FY Dec 2023 | -4.38x |
| FY Dec 2022 | -7.35x |
| FY Dec 2021 | -6.81x |
| Jun 2026 | -2.13x |
| Mar 2026 | -3.37x |
| Dec 2025 | -3.87x |
| Sep 2025 | -2.78x |
| Jun 2025 | -2.57x |
| Mar 2025 | -1.80x |
| Dec 2024 | -1.50x |
| Sep 2024 | -3.35x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-124.4%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PTPI
| FY Dec 2025 | n/a |
| FY Dec 2024 | -622.1% |
| FY Dec 2023 | -56.7% |
| FY Dec 2022 | -76.7% |
| FY Dec 2021 | -33.9% |
| Jun 2026 | -124.4% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -216.6% |
| Jun 2025 | -133.0% |
| Mar 2025 | -14,247% |
| Dec 2024 | -622.1% |
| Sep 2024 | -94.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-58.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PTPI
| FY Dec 2025 | +24.2% |
| FY Dec 2024 | -64.5% |
| FY Dec 2023 | -24.7% |
| FY Dec 2022 | -40.2% |
| FY Dec 2021 | -13.1% |
| Jun 2026 | -58.5% |
| Mar 2026 | +29.0% |
| Dec 2025 | +24.2% |
| Sep 2025 | -52.4% |
| Jun 2025 | -51.1% |
| Mar 2025 | -60.2% |
| Dec 2024 | -64.5% |
| Sep 2024 | -15.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital PTPI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-132.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PTPI
| FY Dec 2025 | n/a |
| FY Dec 2024 | -59.2% |
| FY Dec 2023 | -56.3% |
| FY Dec 2022 | -64.5% |
| FY Dec 2021 | -56.1% |
| Jun 2026 | -132.0% |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -84.0% |
| Jun 2025 | -51.3% |
| Mar 2025 | -95.8% |
| Dec 2024 | -59.2% |
| Sep 2024 | -46.6% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
0.06x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PTPI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.17x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
-$1.7M
market value at close 2026-10-27 on 2026-08-15 shares, plus current debt only, 2021-09-30 (57 months older than the period end), minus cash 2026-06-30
Enterprise value PTPI
| FY Dec 2025 | -$3.1M |
| FY Dec 2024 | $98.7M |
| FY Dec 2023 | $66.0M |
| FY Dec 2022 | $1.2B |
| FY Dec 2021 | $10.9B |
| Jun 2026 | -$1.5M |
| Mar 2026 | -$2.4M |
| Dec 2025 | -$3.1M |
| Sep 2025 | -$3.3M |
| Jun 2025 | -$4.5M |
| Mar 2025 | $85.1M |
| Dec 2024 | $98.7M |
| Sep 2024 | $83.6M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield PTPI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -9.8% |
| FY Dec 2022 | -1.1% |
| FY Dec 2021 | -0.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -6.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing PTPI
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | $5.1M | $5.8M | $6.0M |
| Gross profit | n/a | $3.9M | $4.2M | $3.7M |
| Operating income | -$4.6M | -$4.6M | -$13.6M | -$19.9M |
| Net income | $1.9M | -$14.3M | -$8.2M | -$20.0M |
| EPS (diluted) | -1.56 | -83.47 | -6.35 | -9.68 |
| Operating cash flow | -$6.7M | -$2.6M | -$7.6M | -$12.8M |
| Cash | $5.1M | $1.7M | $13.3M | $9.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
PTPI Stock Sonar score 4/7 axes
Find similar shapesComparePTPI ranks highest on risk and compliance (91st percentile) and growth (34th), and lowest on financial health (26th), among Pharma & Biotech peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
